VLA1553 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Sep 17, 2020 → Oct 15, 2021
NCT ID
NCT04546724About VLA1553 + Placebo
VLA1553 + Placebo is a phase 3 stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04546724. Target conditions include Chikungunya Virus Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04546724 | Phase 3 | Completed |
Competing Products
20 competing products in Chikungunya Virus Infection